Skip to Content
Merck
All Photos(1)

Documents

Y0000479

Chlorpromazine impurity D

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Desmethylchlorpromazine, 3-(2-Chloro-10H-phenothiazin-10-yl)-N-methylpropan-1-amine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H17ClN2S
CAS Number:
1225-64-5
Molecular Weight:
304.84
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

chlorpromazine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C16H17ClN2S/c1-18-9-4-10-19-13-5-2-3-6-15(13)20-16-8-7-12(17)11-14(16)19/h2-3,5-8,11,18H,4,9-10H2,1H3

InChI key

YHFXGBOUSIKGMZ-UHFFFAOYSA-N

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Chlorpromazine impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

G Alfredsson et al.
Acta psychiatrica Scandinavica. Supplementum, 311, 49-74 (1984-01-01)
Schizophrenic patients were treated with fixed doses of sulpiride (800 mg) or chlorpromazine (400 mg) during eight weeks using a double-blind design. In order to examine relationships between pharmacokinetic, clinical and biochemical parameters in relation to treatment the following variables
M Chetty et al.
Therapeutic drug monitoring, 13(4), 350-355 (1991-07-01)
The concentrations of chlorpromazine (CPZ) and six of its metabolites in patient plasma samples that had been stored for 24 h at -20 degrees C, for 1 week at -20 degrees C, and for 4 weeks at -70 degrees C
B Wode-Helgodt et al.
Psychopharmacology, 73(1), 55-62 (1981-01-01)
Efforts to find a correlation between serum levels of chlorpromazine (CPZ) and clinical effect have been rather unsuccessful, which could be due to fluctuations of CPZ and CPZ metabolite levels during treatment, the complicated metabolism of CPZ, or to varying
R C Young
Therapeutic drug monitoring, 8(1), 23-26 (1986-01-01)
Plasma nor1-chlorpromazine (nor1-CPZ) and chlorpromazine concentrations were measured by gas chromatography--mass fragmentometry in 15 inpatients receiving stable doses of chlorpromazine. Nor1-CPZ concentrations averaged 20% of chlorpromazine concentrations and were highly correlated with them. Relative concentrations of nor1-CPZ increased with age.
[Dehalogenation and N-dealkylation of chlorpromazine in patients undergoing chronic treatment].
R Ninci et al.
Bollettino della Societa italiana di biologia sperimentale, 61(8), 1101-1104 (1985-08-30)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service